

**FORM 51-102F3
MATERIAL CHANGE REPORT**

ITEM 1. NAME AND ADDRESS OF COMPANY

EnviroGold Global Limited (the “Issuer”)
810 – 789 West Pender Street
Vancouver, BC V6C 1H2

ITEM 2. DATE OF MATERIAL CHANGE

September 27, 2022

ITEM 3. NEWS RELEASE

The news release was disseminated through the facilities of Globenewswire on September 8, 2022 and subsequently filed on SEDAR.

ITEM 4. SUMMARY OF MATERIAL CHANGE

The Issuer announced the appointment of Mr. Allan Bezanson as a director and Independent Chair of the Board, effective September 1, 2022.

The Issuer also announced the planned transition of Mr. David Cam from Executive Chair to Executive Director of the Board.

ITEM 5. FULL DESCRIPTION OF MATERIAL CHANGE

Effective September 1, 2022, Mr. Allan Bezanson was appointed Independent Chair of the Issuer’s Board. Allan’s successful career in building and investing in high-growth companies spans over 35 years and includes extensive C-Suite and Board level (Director, Executive Chairman) experience. Notable past roles for Allan include serving as Managing Director of Nowco (1978 – 1992), President of Oballan Capital (1997 – 2010), Managing Partner of Cornerstone Capital (2010-2014), Director of Voxel Analytics Corp (2013 – 2021), and CEO & Director of FCF Capital where he led major investments in Polaris Infrastructure and Founders Advantage. Allan currently serves as a Director of Oxford Immune Algorithmics. Allan received a B.Comm, Finance, from Dalhousie University, with an emphasis in derivatives, credit & tax structuring. Allan is a significant shareholder of EnviroGold Global through control of 2706791 Ontario Inc., which owns 15,754,979 shares of NVRO.

In addition to the appointment of Mr. Allan Bezanson, the Issuer also announces the planned transition of Mr. David V. Cam, the Issuer’s founder & principal shareholder, from Executive Chair to Executive Director of the Board. This change will allow Mr. Cam to continue to focus on strategic development initiatives whilst enhancing the board’s independent governance.

ITEM 6. RELIANCE ON SUBSECTION 7.1(2) OR (3) OF NATIONAL INSTRUMENT 51-102

Not Applicable.

ITEM 7. OMITTED INFORMATION

There are no significant facts required to be disclosed herein which have been omitted.

ITEM 8. EXECUTIVE OFFICER

Contact: Dr. Mark B. Thorpe, Director & CEO
Telephone: (416) 777-6720

ITEM 9. DATE OF REPORT

September 27, 2022